A Phase 3 interventional study of Formoterol (OT) in Chronic Obstructive Pulmonary Disease, sponsored by AstraZeneca. Completed at 27 sites in Japan. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2013-01-04.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive — 3 open to participants now, 3 under way, 1 of them phase 3. formoterol · Pulmonary Disease, Chronic Obstructive.
Among the 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive, this one is the 38th largest by enrollment, is one of 2 that started in 2009, is one of 40 in phase 3, and was the 29th registered.
5,527 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →3 of the 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Germany, United Kingdom
Ages 40–80
AstraZeneca · Sites in United States, Argentina, Australia and 34 more countries
Ages 40–80
University of Tennessee Graduate School of Medicine · Sites in United States
Ages 40+
By country, each count listing its studies:
formoterol: first FDA approval 2001 (FORADIL), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 561 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
89 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 251 is above the median of 62 across 3,845 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 120 across the 89 interventional studies. Of the 80 that completed or were terminated, 38 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
68 of 89 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca: 14 open now, 15 under way, 4 of them phase 3. Of 264 finished, 127 (48%) have results posted.
Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, this one is the 79th largest by enrollment of the 194 interventional ones that give a count, is one of 19 that started in 2009, is one of 76 in phase 3, and was the 62nd registered.
AstraZeneca’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 1999.
1 of the studies testing formoterol in Pulmonary Disease, Chronic Obstructive that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07073950AstraZenecaA Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation | 2027-05-31 |
Add it to your calendar (.ics) → With an account.
Among the 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 284 in Pulmonary Disease, Chronic Obstructive:
This tab as a report to print or save as PDF → With an account.
This study is a multicentre, open, randomised, parallel-group study with formoterol 9 μg one inhalation b.i.d, or standard COPD therapy. Standard (reference) COPD treatment arm should be the group to refer to when safety results of formoterol arm will be evaluated. 240 patients with moderate-to-severe COPD will be randomised (120 patients in the formoterol-arm and 120 patients on standard COPD therapy).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Formoterol 9 μg/dose
Drug: Formoterol (OT)
9 μg/dose, Inhaled, twice daily for 52 weeks
Also known as: Oxis Turbuhaler®
Clinical Laboratory Test: Haematology -Erythrocytes
Mean change from Baseline
Time frame: Baseline and week 52
Clinical Laboratory Test: Haematology -Haemoglobin
Change from baseline
Time frame: Baseline and week 52
Clinical Laboratory Test: Haematology-Leucocytes
Change from baseline
Time frame: Baseline and week 52
Clinical Laboratory Test: Haematology-Platelet Count
Change from baseline
Time frame: Baseline and week 52
Clinical Laboratory Test: Haematology Eosinophils
Change from baseline
Time frame: baseline and week 52
Clinical Laboratory Test: Haematology Basophil
Change from baseline
Time frame: Baseline and week 52
Clinical Laboratory Test: Haematology-Lymphocytes
Change from baseline
Time frame: Baseline and week 52
Clinical Laboratory Test: Haematology-Monocytes
Change from baseline
Time frame: Baseline and week 52
Clinical Laboratory Test: Haematology -Neutrophils
Change from baseline
Time frame: Baseline and week 52
Clinical Laboratory Test: Clinical Chemistry- S-Alanine Aminotransferase
Change from baseline
Time frame: Baseline and week 52
Clinical Laboratory Test: Clinical Chemistry-S-Aspartate Aminotransferase
Change from baseline
Time frame: Baseline and week 52
Clinical Laboratory Test: Clinical Chemistry-S-Alkaline Phosphatase (ALP)
Change from baseline
Time frame: Baseline and week 52
Clinical Laboratory Test: Clinical Chemistry-S-Creatinine
Change from Baseline
Time frame: Baseline and week 52
Clinical Laboratory Test: Clinical Chemistry-S-Total Bilirubin
Change from baseline
Time frame: Baseline and week 52
Clinical Laboratory Test: Clinical Chemistry-S-Sodium
Change from baseline
Time frame: Baseline and week 52
Clinical Laboratory Test: Clinical Chemistry-S-Potassium
Change from baseline
Time frame: Baseline and week 52
Clinical Laboratory Test: Clinical Chemistry-S- Calcium
Change from baseline
Time frame: Baseline and week 52
Clinical Laboratory Test: Clinical Chemistry-S-Albumin
Change from baseline
Time frame: Baseline and week 52
Clinical Laboratory Test: Clinical Chemistry-S-Total Protein
Change from baseline
Time frame: Baseline and week 52
Clinical Laboratory Test: Clinical Chemistry - S-Blood Urea Nitrogen (BUN)
Change from baseline
Time frame: Baseline and week 52
Vital Signs- Sitting SBP
Change from baseline
Time frame: Baseline and week 52
Vital Signs- Sitting DBP
Change from baseline
Time frame: Baseline and week 52
Vital Signs - Pulse Rate
Change from baseline
Time frame: Baseline and week 52
ECG Variables - Heart Rate
Change from baseline
Time frame: Baseline and week 52
ECG Variables - QT Interval
Change from baseline
Time frame: Baseline and week 52
ECG Variables - QTcB Interval
Change from baseline
Time frame: Baseline and week 52
ECG Variables QTcF Interval
Change from baseline
Time frame: Baseline and week 52
ECG Variables RR Interval
Change from baseline
Time frame: Baseline and week 52
Forced Expiratory Volume in One Second (FEV1)
The ratio of the average value of available data for mean from Weeks 0, 4, 8, 17, 26, 34, 43 and 52 to the baseline for each treatment group
Time frame: Before randomization, 0, 4, 8, 17, 26, 34, 43 and 52 weeks after randomization
Forced Vital Capacity (FVC)
The ratio of the average value of available data for Weeks 0, 4, 8, 17, 26, 34, 43 and 52 to the baseline for each treatment group
Time frame: Before randomization, 0, 4, 8, 17, 26, 34, 43 and 52 weeks after randomization
Morning Peak Expiratory Flow(PEF)
The change from Run-in period average to Treatment period average for each treatment group
Time frame: Daily during run-in period (14 - 18 days before Randomisation visit)and daily during 52-week randomization treatment
Evening Peak Expiratory Flow (PEF)
The change from Run-in period average to Treatment period average for each treatment group
Time frame: Daily during run-in period (14 - 18 days before Randomisation visit) and daily during 52-week randomization treatment
Night-time Awakening Due to Chronic Obstructive Pulmonary Disease (COPD) Symptoms
There are 5 alternatives (scored 0 to 4, with 4 being the most severe condition). The change from Run-in period average to Treatment period average for each treatment group
Time frame: Daily during run-in period (14 - 18 days before Randomisation visit ) and daily during 52-week randomization treatment
Daytime Breathlessness Due to Chronic Obstructive Pulmonary Disease (COPD) Symptoms
There are 5 alternatives (scored 0 to 4, with 4 being the most severe condition). The change from Run-in period average to Treatment period average for each treatment group
Time frame: Daily during run-in period (14 - 18 days before Randomisation visit ) and daily during 52-week randomization treatment
Daytime Cough Due to Chronic Obstructive Pulmonary Disease (COPD) Symptoms
There are 5 alternatives (scored 0 to 4, with 4 being the most severe condition). The change from Run-in period average to Treatment period average for each treatment group
Time frame: Daily during run-in period (14 - 18 days before Randomisation visit) and daily during 52-week randomization treatment
Total Chronic Obstructive Pulmonary Disease (COPD) Symptom Score
The Total COPD Symptom score is the sum of the measures night-time awakening, breathlessness and cough, ranges from 0 to 12 with 12 being the most severe. The change from Run-in period average to Treatment period average for each treatment group.
Time frame: Daily during run-in period (14 - 18 days before Randomisation visit ) and daily during 52-week randomization treatment
Number of COPD Exacerbations Over the Treatment Period
A Chronic Obstructive Pulmonary Disease (COPD) exacerbation was defined as worsening in COPD symptoms requiring treatment with either a course of systemic steroid or hospitalisation. Number of COPD exacerbation during 52-week randomization treatment was presented here.
Time frame: Daily during 52-week randomization treatment
Use of SABA (Salbutamol) as Reliever Medication
The change from Run-in period average to Treatment period average for each treatment group.
Time frame: Daily during run-in period (14 - 18 days before Randomisation visit ) and daily during 52-week randomization treatment
St George's Respiratory Questionnaire (SGRQ) Total Score
SGRQ total score shows the impact of COPD on patient's health status, and expressed as a percentage of impairment with scale from 0 (best health status) to 100 (worst possible status). A negative rate of decline shows decreasing SGRQ total score (or improved health) over time, while a positive value shows increasing score (or worsen health). The change from Run-in period average to Treatment period average for each treatment group
Time frame: Daily during run-in period (14 - 18 days before Randomisation visit ) and daily during 52-week randomization treatment
The first participant entered the study on 18 December 2009, and the last participant completed the study on 20 July 2011. A total of 320 participants were enrolled at 30 centers in Japan, and 251 participants who fulfilled the randomization criteria were randomized.
| Milestone | Formoterol | Standard Treatment |
|---|---|---|
| Started | 125 | 126 |
| Completed | 108 | 117 |
| Not completed | 17 | 9 |
| Withdrew: Adverse event | 10 | 5 |
| Withdrew: Withdrawal by subject | 4 | 2 |
| Withdrew: Development of study-specific withdrawal | 1 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Sever non-compliance to protocol | 1 | 0 |
| Withdrew: Pi's decision | 0 | 1 |
Mean change from Baseline
| erythrocytes counts x10000/μl | Arm 1 - Formoterol | Arm 2 - Standard Treatment |
|---|---|---|
| Clinical Laboratory Test: Haematology -Erythrocytes | -6.25 ± 23.8 | -5.2 ± 27.5 |
Change from baseline
| g/dL | Arm 1 - Formoterol | Arm 2 - Standard Treatment |
|---|---|---|
| Clinical Laboratory Test: Haematology -Haemoglobin | -0.29 ± 0.73 | -0.20 ± 1.14 |
Change from baseline
| leukocyte count/µL | Arm 1 - Formoterol | Arm 2 - Standard Treatment |
|---|---|---|
| Clinical Laboratory Test: Haematology-Leucocytes | -132.1 ± 1535.3 | -289.5 ± 1284.6 |
Change from baseline
| Platelet Count x10000/μl | Arm 1 - Formoterol | Arm 2 - Standard Treatment |
|---|---|---|
| Clinical Laboratory Test: Haematology-Platelet Count | 0.17 ± 3.29 | -0.40 ± 4.06 |
Change from baseline
| percentage of Eosinophil | Arm 1 - Formoterol | Arm 2 - Standard Treatment |
|---|---|---|
| Clinical Laboratory Test: Haematology Eosinophils | 0.49 ± 2.21 | 0.45 ± 2.45 |
Change from baseline
| percentage of Basophil | Arm 1 - Formoterol | Arm 2 - Standard Treatment |
|---|---|---|
| Clinical Laboratory Test: Haematology Basophil | 0.05 ± 0.37 | 0.01 ± 0.35 |
Change from baseline
| percentage of Lymphocyte | Arm 1 - Formoterol | Arm 2 - Standard Treatment |
|---|---|---|
| Clinical Laboratory Test: Haematology-Lymphocytes | -1.31 ± 7.86 | -0.43 ± 7.06 |
Change from baseline
| percentage of Monocyte | Arm 1 - Formoterol | Arm 2 - Standard Treatment |
|---|---|---|
| Clinical Laboratory Test: Haematology-Monocytes | -0.01 ± 1.55 | -0.03 ± 1.49 |
Change from baseline
| percentage of Neutrophil | Arm 1 - Formoterol | Arm 2 - Standard Treatment |
|---|---|---|
| Clinical Laboratory Test: Haematology -Neutrophils | 1.92 ± 8.32 | -0.28 ± 7.64 |
Change from baseline
| U/l | Arm 1 - Formoterol | Arm 2 - Standard Treatment |
|---|---|---|
| Clinical Laboratory Test: Clinical Chemistry- S-Alanine Aminotransferase | -0.3 ± 10.0 | 4.9 ± 65.9 |
Change from baseline
| U/l | Arm 1 - Formoterol | Arm 2 - Standard Treatment |
|---|---|---|
| Clinical Laboratory Test: Clinical Chemistry-S-Aspartate Aminotransferase | 0.4 ± 12.0 | 2.6 ± 39.3 |
Change from baseline
| U/l | Arm 1 - Formoterol | Arm 2 - Standard Treatment |
|---|---|---|
| Clinical Laboratory Test: Clinical Chemistry-S-Alkaline Phosphatase (ALP) | 3.8 ± 44.7 | -4.4 ± 52.9 |
Change from Baseline
| mg/dL | Arm 1 - Formoterol | Arm 2 - Standard Treatment |
|---|---|---|
| Clinical Laboratory Test: Clinical Chemistry-S-Creatinine | 0.009 ± 0.089 | 0.021 ± 0.117 |
Change from baseline
| mg/dL | Arm 1 - Formoterol | Arm 2 - Standard Treatment |
|---|---|---|
| Clinical Laboratory Test: Clinical Chemistry-S-Total Bilirubin | 0.05 ± 0.22 | 0.02 ± 0.19 |
Change from baseline
| mEq/l | Arm 1 - Formoterol | Arm 2 - Standard Treatment |
|---|---|---|
| Clinical Laboratory Test: Clinical Chemistry-S-Sodium | -0.3 ± 1.9 | -0.2 ± 2.0 |
Change from baseline
| mEq/L | Arm 1 - Formoterol | Arm 2 - Standard Treatment |
|---|---|---|
| Clinical Laboratory Test: Clinical Chemistry-S-Potassium | -0.15 ± 0.34 | -0.07 ± 0.37 |
Change from baseline
| mg/dl | Arm 1 - Formoterol | Arm 2 - Standard Treatment |
|---|---|---|
| Clinical Laboratory Test: Clinical Chemistry-S- Calcium | -0.02 ± 0.42 | -0.03 ± 0.35 |
Change from baseline
| g/dl | Arm 1 - Formoterol | Arm 2 - Standard Treatment |
|---|---|---|
| Clinical Laboratory Test: Clinical Chemistry-S-Albumin | 0.00 ± 0.28 | 0.00 ± 0.23 |
Change from baseline
| g/dl | Arm 1 - Formoterol | Arm 2 - Standard Treatment |
|---|---|---|
| Clinical Laboratory Test: Clinical Chemistry-S-Total Protein | -0.05 ± 0.40 | -0.09 ± 0.37 |
Change from baseline
| mg/dl | Arm 1 - Formoterol | Arm 2 - Standard Treatment |
|---|---|---|
| Clinical Laboratory Test: Clinical Chemistry - S-Blood Urea Nitrogen (BUN) | -0.48 ± 4.00 | 0.07 ± 3.99 |
Change from baseline
| mmHg | Arm 1 - Formoterol | Arm 2 - Standard Treatment |
|---|---|---|
| Vital Signs- Sitting SBP | -2.1 ± 14.8 | -2.1 ± 16.4 |
Change from baseline
| mmHg | Arm 1 - Formoterol | Arm 2 - Standard Treatment |
|---|---|---|
| Vital Signs- Sitting DBP | -2.7 ± 8.9 | -3.5 ± 10.1 |
Change from baseline
| beats/minute | Arm 1 - Formoterol | Arm 2 - Standard Treatment |
|---|---|---|
| Vital Signs - Pulse Rate | 1.5 ± 10.7 | -0.1 ± 10.2 |
Change from baseline
| beats/min | Arm 1 - Formoterol | Arm 2 - Standard Treatment |
|---|---|---|
| ECG Variables - Heart Rate | 2.0 ± 11.4 | 0.6 ± 12.0 |
Change from baseline
| milisecond | Arm 1 - Formoterol | Arm 2 - Standard Treatment |
|---|---|---|
| ECG Variables - QT Interval | -2.0 ± 22.8 | 2.6 ± 26.7 |
Change from baseline
| milisecond | Arm 1 - Formoterol | Arm 2 - Standard Treatment |
|---|---|---|
| ECG Variables - QTcB Interval | 2.1 ± 20.6 | 1.2 ± 22.2 |
Change from baseline
| milisecond | Arm 1 - Formoterol | Arm 2 - Standard Treatment |
|---|---|---|
| ECG Variables QTcF Interval | 0.5 ± 15.1 | 1.7 ± 19.1 |
Change from baseline
| milisecond | Arm 1 - Formoterol | Arm 2 - Standard Treatment |
|---|---|---|
| ECG Variables RR Interval | -12.1 ± 7.2 | 131.7 ± 124.1 |
The ratio of the average value of available data for mean from Weeks 0, 4, 8, 17, 26, 34, 43 and 52 to the baseline for each treatment group
| percentage of baseline | Arm 1 - Formoterol | Arm 2 - Standard Treatment |
|---|---|---|
| Forced Expiratory Volume in One Second (FEV1) | 101.46 (68.9 to 139.2) | 99.42 (80.3 to 165.1) |
The ratio of the average value of available data for Weeks 0, 4, 8, 17, 26, 34, 43 and 52 to the baseline for each treatment group
| Percentage of baseline | Arm 1 - Formoterol | Arm 2 - Standard Treatment |
|---|---|---|
| Forced Vital Capacity (FVC) | 101.62 (76.9 to 157.3) | 99.13 (75.3 to 163.0) |
The change from Run-in period average to Treatment period average for each treatment group
| Liter/minute (L/min) | Arm 1 - Formoterol | Arm 2 - Standard Treatment |
|---|---|---|
| Morning Peak Expiratory Flow(PEF) | 12.2 ± 34.9 | 7.3 ± 26.2 |
The change from Run-in period average to Treatment period average for each treatment group
| Liter/minute (L/min) | Arm 1 - Formoterol | Arm 2 - Standard Treatment |
|---|---|---|
| Evening Peak Expiratory Flow (PEF) | 9.6 ± 34.0 | 7.9 ± 28.2 |
There are 5 alternatives (scored 0 to 4, with 4 being the most severe condition). The change from Run-in period average to Treatment period average for each treatment group
| units on a scale | Arm 1 - Formoterol | Arm 2 - Standard Treatment |
|---|---|---|
| Night-time Awakening Due to Chronic Obstructive Pulmonary Disease (COPD) Symptoms | 0.0 ± 0.4 | -0.1 ± 0.6 |
There are 5 alternatives (scored 0 to 4, with 4 being the most severe condition). The change from Run-in period average to Treatment period average for each treatment group
| units on a scale | Arm 1 - Formoterol | Arm 2 - Standard Treatment |
|---|---|---|
| Daytime Breathlessness Due to Chronic Obstructive Pulmonary Disease (COPD) Symptoms | -0.2 ± 0.7 | -0.2 ± 0.8 |
There are 5 alternatives (scored 0 to 4, with 4 being the most severe condition). The change from Run-in period average to Treatment period average for each treatment group
| units on a scale | Arm 1 - Formoterol | Arm 2 - Standard Treatment |
|---|---|---|
| Daytime Cough Due to Chronic Obstructive Pulmonary Disease (COPD) Symptoms | -0.2 ± 0.8 | -0.1 ± 0.7 |
The Total COPD Symptom score is the sum of the measures night-time awakening, breathlessness and cough, ranges from 0 to 12 with 12 being the most severe. The change from Run-in period average to Treatment period average for each treatment group.
| units on a scale | Arm 1 - Formoterol | Arm 2 - Standard Treatment |
|---|---|---|
| Total Chronic Obstructive Pulmonary Disease (COPD) Symptom Score | -0.5 ± 1.2 | -0.4 ± 1.4 |
A Chronic Obstructive Pulmonary Disease (COPD) exacerbation was defined as worsening in COPD symptoms requiring treatment with either a course of systemic steroid or hospitalisation. Number of COPD exacerbation during 52-week randomization treatment was presented here.
| number of exacerbations | Arm 1 - Formoterol | Arm 2 - Standard Treatment |
|---|---|---|
| Number of COPD Exacerbations Over the Treatment Period | 27 | 19 |
The change from Run-in period average to Treatment period average for each treatment group.
| Times/Day | Arm 1 - Formoterol | Arm 2 - Standard Treatment |
|---|---|---|
| Use of SABA (Salbutamol) as Reliever Medication | -0.2 ± 0.7 | 0.0 ± 1.1 |
SGRQ total score shows the impact of COPD on patient's health status, and expressed as a percentage of impairment with scale from 0 (best health status) to 100 (worst possible status). A negative rate of decline shows decreasing SGRQ total score (or improved health) over time, while a positive value shows increasing score (or worsen health). The change from Run-in period average to Treatment period average for each treatment group
| units on a scale | Arm 1 - Formoterol | Arm 2 - Standard Treatment |
|---|---|---|
| St George's Respiratory Questionnaire (SGRQ) Total Score | -1.34 ± 8.48 | -0.57 ± 7.78 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Formoterol | — | 20/125 (16%) | 54/125 (43.2%) |
| Standard Treatment | — | 18/126 (14.3%) | 60/126 (47.6%) |
| Event | Formoterol | Standard Treatment |
|---|---|---|
| CHRONIC OBSTRUCTIVE PULMONARY DISEASERespiratory, thoracic and mediastinal disorders | 5/125 | 4/126 |
| PneumoniaInfections and infestations | 4/125 | 1/126 |
| Prostate CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/125 | 2/126 |
| Aortic DissectionVascular disorders | 1/125 | 0/126 |
| Spermatic Cord DisorderReproductive system and breast disorders | 1/125 | 0/126 |
| DepressionPsychiatric disorders | 1/125 | 0/126 |
| Chest X-Ray AbnormalInvestigations | 1/125 | 0/126 |
| Device FailureGeneral disorders | 1/125 | 0/126 |
| PalpitationsCardiac disorders | 1/125 | 0/126 |
| Myocardial IschaemiaCardiac disorders | 1/125 | 0/126 |
| Event | Formoterol | Standard Treatment |
|---|---|---|
| NASOPHARYNGITISInfections and infestations | 42/125 | 53/126 |
| Back PainMusculoskeletal and connective tissue disorders | 13/125 | 2/126 |
| Chronic Obstructive Pulmonary DiseaseRespiratory, thoracic and mediastinal disorders | 9/125 | 5/126 |
| BronchitisInfections and infestations | 5/125 | 9/126 |
| PneumoniaInfections and infestations | 8/125 | 3/126 |
| PharyngitisInfections and infestations | 7/125 | 4/126 |
| DizzinessNervous system disorders | 6/125 | 2/126 |
| RhinitisInfections and infestations | 5/125 | 2/126 |
| ConstipationGastrointestinal disorders | 5/125 | 4/126 |
| ConjunctivitisEye disorders | 5/125 | 5/126 |
| Age Continuous(Years) | Formoterol | Standard Treatment | Total |
|---|---|---|---|
| Mean | 70.8 (43 to 88) | 70.3 (50 to 83) | 70.6 (43 to 88) |
| Sex: Female, Male(Participants) | Formoterol | Standard Treatment | Total |
|---|---|---|---|
| Female | 6 | 9 | 15 |
| Male | 119 | 117 | 236 |
The record gives a start of Dec 2009, a primary completion of Jan 2011 and a completion of Jul 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2013, 2 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Formoterol
Pulmonary Disease, Chronic Obstructive →